Intravitreal dexamethasone (ozurdex) implant for radiation maculopathy secondary to stereotactic radiotherapy for posterior uveal melanoma
Conclusion:
In our experience, intravitreal implantation of 0.7 mg dexamethasone is an anatomically, and to a lesser extent functionally effective procedure for radiation maculopathy after stereotactic radiotherapy for posterior uveal melanoma.
Source: Retinal Cases and Brief Reports - Category: Opthalmology Tags: Case Report Source Type: research
More News: Avastin | Cataracts | Dexamethasone | Diabetes | Endocrinology | Eye Cancers | Eye Implants | Eyes | Glaucoma | Melanoma | Opthalmology | Skin Cancer | Study | Uveal Melanoma | Vitamin A